Lv6
2070 积分 2024-08-13 加入
Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia
2个月前
已完结
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
2个月前
已完结
Mixed cell type in airway inflammation is the dominant phenotype in asthma patients with severe chronic rhinosinusitis
2个月前
已完结
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
2个月前
已完结
[Efficacy and clinical remission in patients with severe asthma and blood eosinophil counts ≥150 cells/μl treated with benralizumab: a sub-analysis of the Phase 3 MIRACLE study]
2个月前
已完结
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
2个月前
已完结
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
2个月前
已完结
Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia
2个月前
已完结
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
2个月前
已完结
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
2个月前
已完结
皖公网安备34019202002308
